These findings were consistent with our previous studies with another anti-HER3 mAb, MM-121/seribantumab, which exerted potent antitumor activity against HER2-positive breast cancer only when MM-121 was combined with paclitaxel [47]. Here, ERBB2 is linked to breast carcinoma.